July 20, 2015 – Early nutrition and adiposity have been linked to atopic dermatitis (AD) development.
July 20, 2015 – Researchers at Yale School of Medicine have successfully treated patients with moderate to severe eczema using a rheumatoid arthritis drug.
July 13, 2015 – Anacor Pharmaceuticals Announces Positive Top-Line Results From Two Phase 3 Pivotal Studies of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis.
June 16,2015 – Dermatologists have long known that available treatments for chronic itch, including eczema, are simply not up to scratch. But scientists have now discovered a new gene that promotes itch, suggesting a way forward for powerful new therapies.
June 1, 2015 – Patients with either vitiligo, especially early-onset disease, or AA, especially alopecia totalis or alopecia universalis, have significantly increased risk for AD.
May 29, 2015 – Linalyl acetate, a fragrance chemical that is one of the main constituents of the essential oil of lavender, is not on the list of allergenic compounds pursuant to the EU Cosmetics Directive. Thus, it does not need to be declared on cosmetic products sold within the EU. Recent studies at the University of Gothenburg have shown that linalyl acetate can cause allergic eczema.
May 7, 2015 – Researchers from St. Jude Children’s Research Hospital have identified a protein that offers a new focus for developing targeted therapies to tame severe inflammation. Targeting this protein has lead to a greater understanding on how mutations in a protein can lead to atopic dermatitis.
May 7, 2015 – Patients with atopic dermatitis had a slightly increased risk of lymphoma, with the severity of atopic dermatitis a potentially significant risk factor, according to recently published study results.
May 7, 2015 – Inflammation, once merely considered the body’s healing response, is now the subject of close scrutiny as a key component of many diseases. Arthritis and inflammation have been linked for decades, but the inflammatory response is also taking center stage in heart disease, cancer, diabetes, asthma, and Alzheimer’s disease.
NEA formed a Scientific Advisory Committee Task Force to conduct a systematic review of topical corticosteroid withdrawal/topical steroid addiction in patients with atopic dermatitis and other dermatoses, and created a NEA education announcement on Topical Steroid Addiction/Withdrawal.